Press Releases

1 2 3 Next

01 July 2016

First-In-Human Study of Immbio’s Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine to be Safe and Immunogenic

ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, reports positive results from the First-in-Human study of its novel vaccine, PnuBioVax™, against the bacterial pathogen Streptococcus pneumoniae (NCT02572635). PnuBioVax was found to be safe and well tolerated, and capable of producing antibody responses against key S. pneumoniae antigens broadly conserved across strains. The data was presented today at the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Glasgow, UK “... Read more

10 December 2015

ImmBio Initiates First-in-Human Studies of its Novel Pneumococcal Vaccine, PnuBioVax

Cambridge, UK, 10 December 2015 — ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, today announces that it has initiated enrolment for a First-in-Human study of its novel vaccine (“PnuBioVax™”) against the bacterial pathogen Streptococcus pneumoniae.... Read more

1 2 3 Next